eligibility_summary
Adults 18–75 with confirmed unresectable locally adv/metastatic NSCLC, prior EGFR-TKI/standard therapy or untreated, ≥1 measurable lesion, ECOG 0–1, life expectancy ≥12 wks, adequate organ function. Exclude active CNS mets/cord compression, uncontrolled pain/effusions, recent cancer therapy/surgery, other cancer ≤5y, ILD/severe lung disease, serious CV/GI or autoimmune disease, recent infection/bleeding/clots, HIV/active HBV/HCV, severe mAb allergy, or psychiatric/poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06092268 evaluates combinations in advanced solid tumors/NSCLC: 1) SHR-A2009 + almonertinib, 2) SHR-A2009 + adebrelimab. Drugs/mechanisms: SHR-A2009 for injection is an investigational antibody-drug conjugate (ADC) that delivers a cytotoxic payload to tumor antigen–expressing cells (the antigen/target is not specified in the registry), Almonertinib mesilate is a third‑generation, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR (including T790M), blocking EGFR signaling, Adebrelimab is an anti‑PD‑L1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD‑1/PD‑L1 to restore T‑cell–mediated antitumor activity. Cells/pathways targeted: tumor cells expressing the ADC’s antigen, EGFR‑mutant NSCLC cells via EGFR pathway inhibition, and the PD‑1/PD‑L1 axis to activate cytotoxic T cells.